ALPHA TAU MEDICAL LTD
DRTSNASDAQ🏆 #2233 by market capUS Equity
$13.35▼ $0.16 (−1.18%)
Pre-market · at closeTrack DRTS
Get earnings, price moves & breaking news on Telegram
24h▼ 1.2%
7d▲ 3.3%
14d▲ 1.4%
30d▼ 12.2%
ytd▲ 171.1%
1y▲ 232.9%
🏦Market Cap
$1.23B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $13.32 – $13.62
- 52-Week Range
- $3.43 – $15.79
- Volume (shares)
- 34,203
- Avg Volume (shares)
- —
- Shares Outstanding
- 92.5M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.66
- Dividend Yield
- —
- Dilution (1yr)
- +22.2%
ALPHA TAU MEDICAL LTD
DRTSFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$42M▲ +17.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$33M▲ +48.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
85.7M▲ +22.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$2M▼ −$3M YoY
StockOtter · stockotter.spaceAbout ALPHA TAU MEDICAL LTD
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.